AS03A-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age

Clinical Infectious Diseases

Volumn 51, Issue 6, 2010, Pages 668-677

  Roman, François ^a   Vaman, Tejaswini ^a   Kafeja, Froukje ^b   Hanon, Emmanuel ^a   Van Damme, Pierre ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AS 03; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEASONAL INFLUENZA; SHIVERING; SIDE EFFECT; SWEATING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINATION; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 77955937857     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655830     Document Type: Article

References (33)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360(25): 2605-2615.
2. World Health Organization (WHO). Statement to the press by WHO Director- General Dr Margaret Chan. 11 June 2009. World now at the start of 2009 influenza pandemic. 11 June 2009. http://www.who.int/mediacentre/ news/statements/2009/ h1n1-pandemic-phase6-20090611/en/. Accessed 17 May 2010.
3. World Health Organization. Global Alert and Response (GAR). Pandemic (H1N1) 2009-update 96. 16 April 2010. http://www.who.int/ csr/don/2010-04-16/en/ index.html. Accessed 4 May 2010.
4. Centers for Disease Control. Use of influenza A (H1N1) 2009 monovalent vaccine recommendations of the advisory committee on immunization practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep 2009; 58 (RR-10):1-8.
5. European Centre for Disease Prevention and Control (ECDC).ECDCinterim guidance. Use of specific pandemic influenza vaccines during the H1N1 2009 pandemic. August 2009. http://www.ecdc.europa.eu/en/publications/Publi cations/0908-GUI-Pandemic-Influenza-Vaccines-during-the-H1N1-2009-Pandemic.pdf. Accessed 17 May 2010.
6. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8(10):650-658.
7. Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine 2007; 25(27):4983-4984.
8. Gasparini R, Schioppa F, Lattanzi M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010; 64(4):432-438.
9. Nicoll A. Children, avian influenza H5N1 and preparing for the next pandemic. Arch Dis Child 2008; 93:433-438.
10. Schwarz TF, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27(45):6284-6290.
11. Clark T, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-2435.
12. Greenberg M, Lai M, Hartel G, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-2413.
13. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375(9708):41-48.
14. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28(7): 1740-1745.
15. Zhu F, Wang H, Fang H, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-2423.
16. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375(9708):49-55.
17. GlaxoSmithKline Biologicals. Immunogenicity, safety and reactogenicity of GSK Biologicals' influenza GSK2340272A and Fluarix™ 2009-2010 vaccines when co-administered in elderly subjects aged 61 years and older. http://www.gsk-clinicalstudyregister.com/files/pdf/ 27869.pdf. Accessed 17 May 2010.
18. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03(A)- adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-857.
19. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26(50):6383-6391.
20. European Medicines Agency (EMEA). Committee for HumanMedicinal Products (CHMP). Guideline on influenza vaccine prepared fromviruses with the potential to cause a pandemic and intended for use outside of the core dossier context. Doc. ref. EMEA/CHMP/VWP/263499/2006. London, 24 January 2007. http://www.emea.europa.eu/docs/en-GB/ document-library/Scientific-guideline/ 2009/09/WC500003872.pdf. Accessed 4 May 2010.
21. GlaxoSmithKline. Pandemrix suspension and emulsion for emulsion for injection. Summary of product characteristics. 2 March 2010.
22. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370(9587):580-589.
23. Hehme N, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix. Clin Drug Invest 2002; 22:751-769.
24. GlaxoSmithKline Biologicals. A phase II, randomised, open study to evaluate the immunogenicity and safety of a single or double-dose of the pandemic influenza candidate vaccine given in a two-administration schedule (21 days apart) in adults over 60 years of age. http:// www.gsk- clinicalstudyregister.com/files/pdf/20171.pdf. Accessed 4 May 2010.
25. Rumke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26(19):2378-2388.
26. Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999; 159(2):182-188.
27. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7(5):385-394.
28. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272(21): 1661-1665. (Pubitemid 24359136)
29. Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology 2007; 53(6):411-418.
30. Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007; 79(3):320-325.
31. Pyhala R, Kumpulainen V, Alanko S, Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994; 12(10):947-952.
32. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453(7195):667-671.
33. Bodewes R, Kreijtz JH, Baas C, et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 2009; 4(5):e5538.